PubMed

Combination pharmacotherapy for cardiovascular disease.

Combination Pharmacotherapy and Public Health Research Working Group.

Ann Intern Med. 2005 Oct 18;143(8):593-9. Review. Erratum in: Ann Intern Med. 2006 Jul 4;145(1):79. PMID: 16230726 [PubMed - indexed for MEDLINE]Related articlesFree article

Preventing cardiovascular disease in the 21st century: therapeutic and preventive implications of current evidence.

Daviglus ML, Lloyd-Jones DM, Pirzada A.

Am J Cardiovasc Drugs. 2006;6(2):87-101. Review.PMID: 16555862 [PubMed - indexed for MEDLINE]Related articles

Multi-constituent cardiovascular pills (MCCP)--challenges and promises of population-based prophylactic drug therapy for prevention of heart attack.

Jamieson MJ, Naghavi M.

Curr Pharm Des. 2007;13(10):1069-76. Review.PMID: 17430169 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.

Gaziano TA, Opie LH, Weinstein MC.

Lancet. 2006 Aug 19;368(9536):679-86. Review.PMID: 16920473 [PubMed - indexed for MEDLINE]Related articlesFree article

[Development of antituberculous drugs: current status and future prospects]

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese. PMID: 17240921 [PubMed - indexed for MEDLINE]Related articles

Polypharmacotherapy for primary prevention of cardiovascular disease.

Xavier D, Devereaux PJ, Goyal A, Pais P, Yusuf S.

Indian Heart J. 2008 Mar-Apr;60(2 Suppl B):B29-33. Review.PMID: 19359761 [PubMed - indexed for MEDLINE]Related articles

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.PMID: 17408535 [PubMed - indexed for MEDLINE]Related articlesFree article

The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.

Hoerger TJ, Ahmann AJ.

J Manag Care Pharm. 2008 Feb;14(1 Suppl C):S2-14; quiz 15-6. Review.PMID: 18240890 [PubMed - indexed for MEDLINE]Related articlesFree article

Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.

Annemans L, Lamotte M, Kubin M, Evers T, Verheugt FW.

Int J Clin Pract. 2006 Sep;60(9):1129-37.PMID: 16939558 [PubMed - indexed for MEDLINE]Related articles

The impact of prevention on reducing the burden of cardiovascular disease.

Kahn R, Robertson RM, Smith R, Eddy D.

Circulation. 2008 Jul 29;118(5):576-85. Epub 2008 Jul 7.PMID: 18606915 [PubMed - indexed for MEDLINE]Related articlesFree article

The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.

Hennekens CH, Schneider WR.

Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107. Review.PMID: 18095910 [PubMed - indexed for MEDLINE]Related articles

Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.

Sanz G, Fuster V.

Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):101-10. Epub 2008 Dec 23. Review.PMID: 19104519 [PubMed - indexed for MEDLINE]Related articles

Reducing the growing burden of cardiovascular disease in the developing world.

Gaziano TA.

Health Aff (Millwood). 2007 Jan-Feb;26(1):13-24.PMID: 17211010 [PubMed - indexed for MEDLINE]Related articlesFree article

Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.

Stafford RS, Monti V, Ma J.

PLoS Med. 2005 Dec;2(12):e353. Epub 2005 Nov 15.PMID: 16277554 [PubMed - indexed for MEDLINE]Related articlesFree article

Can risk factor modification reduce cardiovascular morbidity and mortality in minority populations?

Randall OS, Retta TM, Ordor OE, Courtney BL.

Prev Med. 1996 Jan-Feb;25(1):61-2.PMID: 8778768 [PubMed - indexed for MEDLINE]Related articles

The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.

Nichols GA, Koro CE, Chan W, Bowlin SJ, Sprecher DL.

Clin Ther. 2006 Feb;28(2):243-50.PMID: 16678645 [PubMed - indexed for MEDLINE]Related articles

Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs.

Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, Rodgers A.

Lancet. 2007 Dec 15;370(9604):2054-62. Epub 2007 Dec 11. Review.PMID: 18063025 [PubMed - indexed for MEDLINE]Related articles

Decision-making using absolute cardiovascular risk reduction and incremental cost-effectiveness ratios: a case study.

Ker JA, Oosthuizen H, Rheeder P.

Cardiovasc J Afr. 2008 Mar-Apr;19(2):97-101.PMID: 18516355 [PubMed - indexed for MEDLINE]Related articlesFree article

A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.

Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L.

Intern Med. 2007;46(4):157-62. Epub 2007 Feb 15.PMID: 17301509 [PubMed - indexed for MEDLINE]Related articlesFree article

Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia.

Hennekens CH.

J Clin Psychiatry. 2007;68 Suppl 4:4-7. Review.PMID: 17539693 [PubMed - indexed for MEDLINE]Related articles